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Abstract
Background: Trauma plays an important role in the experience of many patients with substance
use disorder, but is relatively under-studied particularly in Australia. The present survey examined
the lifetime prevalence of various forms of trauma including driving careers in the context of
relevant medical conditions.
Methods: A survey was undertaken in a family medicine practice with a special interest in addiction
medicine in Brisbane, Australia.
Results: Of 350 patients surveyed, 220 were substance dependent, and 130 were general medical
patients. Addicted patients were younger (mean ± S.D. 33.72 ± 8.14 vs. 44.24 ± 16.91 years, P <
0.0001) and had shorter driving histories (15.96 ± 8.50 vs. 25.54 ± 15.03 years, P < 0.0001). They
had less driving related medical problems (vision, spectacle use, diabetes) but more fractures,
surgical operations, dental trauma and assaults. Addicted patients also had significantly worse
driving histories on most parameters measured including percent with driving suspensions (O.R. =
7.70, C.I. 4.38–13.63), duration of suspensions (1.71 ± 3.60 vs. 0.11 ± 0.31 years, P < 0.0001),
number of motor vehicle collisions (2.00 ± 3.30 vs. 1.10 ± 1.32, P = 0.01), numbers of cars repaired
(1.73 ± 3.59 vs. 1.08 ± 1.60, P = 0.042), rear end collisions (O.R. = 1.90, CI 1.13–3.25), running
away after car crashes (O.R. = 26.37, CI 4.31–1077.48), other people hospitalized (O.R. = 2.00, C.I.
0.93–4.37, P = 0.037) and people killed (17 vs. 0 P = 0.0005). Upon multivariate analysis group
membership was shown to be a significant determinant of both cars repaired and cars hit when
controlled for length of driving history. Hence use of all types of drugs (O.R. = 10.07, C.I. 8.80–
14.72) was more common in addicted patients as were general (O.R. = 3.64, C.I. 2.99–4.80) and
road (O.R.= 2.73, C.I. 2.36–3.15) trauma.
Conclusion: This study shows that despite shorter driving histories, addicted patients have worse
driving careers and general trauma experience than the comparison group which is not explained
by associated medical conditions. Trauma is relevant to addiction management at both the patient
and policy levels. Substance dependence policies which focus largely on prevention of virus
transmission likely have too narrow a public health focus, and tend to engender an unrealistically
simplistic and trivialized view of the addiction syndrome. Reduction of drug driving and drug related
trauma likely require policies which reduce drug use per se, and are not limited to harm reduction
measures alone.
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Background
From a phenomenological and pathophysiological per-
spective the substance dependent lifestyle is a complex
mix of many factors including chemical, nutritional,
genetic, judicial, congenital, social, familial and environ-
mental factors. Trauma is one element which is often
overlooked [1] and tends to compound and exacerbate
many of the other aspects of this complex lifestyle.
Trauma has the advantage of being relatively easy to study
retrospectively by formalized questionnaire.
The attention of this clinic was drawn to the contribution
of trauma in our patients' lives principally by two sets of
circumstances. For some time the appalling state of our
patient's teeth has been of major concern, from the point
of view of aesthetic aspects, secondary nutritional com-
promise, the high level of associated loco-regional com-
plications by way of the frequent dental abscesses, and
also for possibly potentiating distant disease by systemic
immune stimulation as has been suggested for some time
by the National Institute for Dental and Craniofacial
Research [2,3] and others [4,5]. A previous report from
this clinic had identified that trauma was an important
factor in serious dental loss [6]. This suggested that dental
trauma may be associated with other kinds of trauma in
our patients' lives which might contribute to a better
understanding of the clinical syndrome of substance
dependence. Secondly many patients have been mention-
ing during the course of their clinical consultations that
they had been involved in motor vehicle accidents. Curi-
ously, this was usually done in a fairly off handed way. My
interest having been aroused and after making further
enquiries it appeared that a frequent mechanism of acci-
dent involved collisions often into the back of another
vehicle. The predominant pattern appeared to be that gen-
eral medical patients had someone run into the back of
their vehicle, whilst the substance dependent patients
appeared to be running into the rear of cars often parked
at traffic lights. Hence issues of driver inattention or men-
tal compromise appeared to be potentially operative.
Motor vehicle trauma has been reported to be associated
with over 300,000 deaths annually on a global scale [7].
Up to 25% of accidents involve drug affected drivers, and
the commonest agent implicated is frequently cannabis
which is said to be implicated in up to 32% – 46% of cases
[6,7]. The population frequency of drug driving has been
found to be about 4% in both Australia and the USA [7].
Cannabis has been reported as featuring prominently in
drug driving incidents in many nations including Swe-
den[8], Spain [9], Italy [10], Netherlands [11], France [12-
14], USA [15-17], Australia [7,18-21], and from multina-
tional collaborations [19]. Poor driving performance
including drug affected driving has been linked with devi-
ant attitudes in other dimensions [22-24] and particularly
perceived risks of detection [25-27]. Literature reports
exist of impaired driver performance by opiate main-
tained patients treated with methadone in association
with both peak and trough levels of methadone [28] and
by both prescribed and illicit supplementary drugs
[29,30].
The author runs a family medical clinic in Brisbane, Aus-
tralia, with a special interest in the management of chem-
ical addictions. This exposure therefore furnishes access to
both substance use disorder (SUD) and general medical
(N-SUD) patients and this seemed to provide an ideal
opportunity to compare an SUD group with a conven-
ience comparison sample group. Having completed and
analyzed the cross-sectional survey these initial impres-
sions have been largely confirmed. Indeed the very large
degree to which many of the relevant pathologies were
elevated amongst the SUD group had not been foreseen.
As such these findings carry major implications for drug
policy implementation in view of the inordinate peril to
which the general public is exposed during the course of
SUD patients procuring, using and travelling to and from
their point of drug purchase [21,31]. This has ramifica-
tions for drug policy administration in that any policy
which increases drug use must necessarily incur unavoid-
able public risk associated with drug users' access issues,
and also for programs such as random drug driver screen-
ing which are increasingly generating interest in many
nations [18,20,32-35]. In particular it suggests that poli-
cies such as harm reduction as it is usually framed which
condone drug use per se [36] and focus unduly on the lim-
itation of the spread of blood borne viruses (BBV's)
[36,37], are too narrow in their purview and tend to pro-
mote a picture of substance dependence which is unreal-
istically benign. The marked extent to which the odds
ratios of driving related trauma are elevated in SUD
groups, together with the clear association with other
forms of trauma imply that drug use itself must be cur-
tailed to control these problems. Of interest these findings
have come at a time when Queensland has introduced a
drug driver screening program beginning in December
2007.
Methods
Patient recruitment
Consecutive patients presenting to our clinic were asked
by the secretarial staff to complete the survey at the time
of their presentation to the clinic. The survey was self
administered. Patients were not paid for their participa-
tion in the study. There were no exclusions, except that the
survey was aimed at present or past drivers of cars or riders
of motorcycles.Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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Survey completion and analysis
The surveys were completed unsupervised by patients in
hardcopy. Results were then entered into a Microsoft Excel
spreadsheet for data analysis.
Clinical activity summaries
Statements of clinical activity are provided by Queensland
Health from their database to practitioners upon request
on an approximately annual basis. Information from such
statistical summaries is included as appropriate.
Statistics
Categorical data were analyzed, and significance levels,
odds ratios and confidence intervals determined by the
EpiInfo program from the Centres for Disease Control
Atlanta, Georgia. Where a numerator was zero, a correc-
tion to unity was introduced to allow calculation of an
odds ratio [38] as indicated in the text. Fisher exact test
with two tails was used where numbers in 2 × 2 tables
were less than 5. Standard adjustments to the t-test
degrees of freedom (df) were applied when variances
appeared unequal. This resulted in decimal values for the
df. Continuous variables which were normally distributed
were analyzed by a two tailed Student's t-test with differ-
ent variances in the statistical software program "Statis-
tica" from Statsoft, Tulsa, Oklahoma. Continuous
variables which were not normally distributed, particu-
larly motor vehicle trauma were compared with the non-
parametric Mann-Whitney test. "Statistica" was used to
prepare graphs and for multivariate analysis. Square root
transforms were applied to non-normally distributed
vehicular trauma data prior to multiple regression proce-
dures. Multivariate regression was performed in the Gen-
eral Regression Module of Statistica on a personal
computer running a Windows-XP platform. P < 0.05 was
considered significant.
Patient consent, confidentiality and ethical review. All
patients consented to be involved in this study. Strict
patient confidentiality was assured at all times. Patient
names were not collected at any stage. The study was
reviewed by the Human Research Ethics Committee
(HREC) of the Southcity Family Medical Centre which is
a National Health and Medical Research Committee regis-
tered HREC. This study was in compliance with the Dec-
laration of Helsinki for human experimentation.
Results
The survey was undertaken over two weeks in October
2007. 350 patients completed the survey. During that
time we performed 660 consultations including repeat
visits. However the exact survey completion rate is not
known. It is however likely to be of the order of 350/660
= 53.0%.
Queensland Health statistics show that this clinic has
been responsible for 3,518 of 5,539 (63.5%) registered
buprenorphine withdrawal patients in Queensland
2001–2006, and for 8,044 of 10,987 (73.2%) episodes of
buprenorphine withdrawal in that same period.
Table 1 lists socio-demographic information of the survey
group. There were 220 and 130 patients respectively in the
SUD and N-SUD groups. The ages were significantly dif-
ferent with means (± S.D.) of 33.72 ± 8.14 and 44.24 ±
16.91 years in the SUD and N-SUD groups respectively
(Student's t = -6.91, df = 167.23, P < 0.0001) The median
ages for the two groups were 32 and 44. As these different
age distributions between substance dependent and med-
ical patients impacted on the subsequent interpretation of
the results derived from the remainder of the survey the
frequency histograms for the distribution of ages are pre-
sented in Figure 1A. Figure 1B illustrates similar frequency
histogram data for the years of driving experience
(described below).
The proportion of drivers in the SUD group was signifi-
cantly less 83.03% vs. 92.31% than the N-SUD group
(O.R. = 0.41, 95%C.I. 0.18–0.89, Chi Squ = 5.99, df = 1,
P = 0.0287). The sex structure of the two groups was sim-
ilar with 70.78% and 61.07% male respectively (Table 1,
Chi Squared = 3.49, df = 1, P = 0.087). The racial compo-
sition of the two groups was also similar although with
somewhat more people of Aboriginal and Torres Strait
Islander (ATSI) background in the SUD group (6.39% vs.
1.53%, Fisher Exact test P = 0.0363).
The drug use is shown in Table 2 which lists the presence
or absence of the various markers in its first half and the
specific use rates of selected drugs in its lower half. Our
SUD patients used more of all classes of drugs than the N-
SUD group. High risk alcohol consumption was deter-
mined by asking respondents directly if they consumed
Table 1: Sociodemographic Characteristics
SUD N-SUD P*
N, Age & Sex
Sample Size 220 130
Age 33.72 (8.14) 44.24 (16.91) <0.0001
% Drive 83.03% 92.31% 0.0287
% Male 70.78% 61.07% 0.0875
Racial Background
Asian-Australian 9.13% 6.11% 0.5070
ATSI 6.39% 1.53% 0.0315
African-Australian 0.91% 0.00% 0.2681
Latino-Australian 0.91% 1.53% 0.6202
* – Chi Squared test, df = 1.
ATSI – Aboriginal and Torres Strait IslanderSubstance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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more than 30 standard drinks weekly. The heroin use rate
0.62 ± 0.72 g/d for a mean of 13.64 ± 10.26 years for a
total lifetime maximum exposure of 7.56 ± 11.40 gram-
years is typical of the use level defined in other surveys in
this clinic, and similar to other surveys in this country of
opiate dependent patients in treatment. The mean
buprenorphine dose of our patients was 4.64 ± 4.77 mg.
As listed patients consumed a variety of other prescribed
medications. When all nine of these drug use categories
were considered together in a sequential Chi-squared
analysis there was significant elevation of drug use in the
SUD group overall (Chi Squ. = 455.38, df = 8, O.R. =
10.07, 95% C.I. 8.80–14.72, P < 0.0001).
We wished to study if associated medical conditions
might explain a presumed increase in the lifetime preva-
Frequency histograms of A: Age profile and B: Driving history durations Figure 1
Frequency histograms of A: Age profile and B: Driving history durations.Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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lence of trauma. Various medical and traumatic condi-
tions are therefore listed in Table 3. Despite being much
younger, SUD patients described both more fits (17.35%
vs. 3.82%, Student's t = 4.47, df = 336.77, P < 0.0001) and
more diagnosed epilepsy (3.65% vs. 0.00%, Student's t =
2.87, df = 216, P = 0.00044). There was marginally less
vision problems in the SUD group (25.11% vs. 34.35%,
Student's t = -1.81, df = 253.99, P = 0.0711), and less
wearing of spectacles in SUD patients (17.35% vs.
53.44%, Student's t = -6.94, df = 224.80, P < 0.0001).
Consistent with a younger age, diabetes was also less fre-
quent amongst the SUD group 1.37% vs. 6.11% (Stu-
dent's t = -2.08, df = 171.49, P = 0.0381), but the use of
insulin was no different (4.11% vs. 4.58%, Student's t = -
0.16, df = 270.33, P = 0.87).
Almost all of the traumatic conditions listed in Table 3
were more common in the SUD group. Amongst this
group of complaints it is important to note that both the
presence of bone fracture and the fracture number was
higher in the SUD group. This is clearly a marker of rela-
tively severe trauma. A further marker of severity of
trauma is the increased number of surgical procedures for
fracture (0.49 ± 1.16 vs. 0.16 ± 0.46, Student's t = 3.84, df
= 306.95, P = 0.0002). There were higher rates of being
bashed, assaulted and having a tooth traumatically
knocked out. The single exceptional condition which was
not more frequent in the SUD group was the number of
surgical operations. However when multiple regression
was used to control for the effect of age on surgical expo-
sure, SUD group membership was significant (Student's t
= 3.14, P = 0.0018). When these five various traumatic
conditions were analyzed sequentially by Chi squared
tables non-vehicular traumatic conditions were more
common in the SUD group (Chi Squ. = 134.72, df = 4,
O.R. = 3.64, C.I. 2.99–4.80, P < 0.0001).
Table 2: Drug Use
SUD N-SUD P*
Categorical Dataa
Heroin 80.37% 0.00% <0.0001
Morphine 29.68% 3.05% <0.0001
Cannabis 44.95% 6.87% <0.0001
Amphetamine 30.59% 0.76% <0.0001
Benzodiazepines 17.81% 0.00% <0.0001
Alprazolam 14.61% 0.00% <0.0001
Tobacco 77.17% 25.19% <0.0001
Alcohol 44.66% 29.77% 0.0064
High Risk Alcohol 34.25% 6.87% <0.0001
Quantitative Datab
Heroin Dose (g) 0.61 (0.72) 0.00 (0.00) -
Age Heroin Commencement (Yrs) 19.77 (8.34) 0.60 (3.98) <0.0001
Duration Heroin Use (Years) 13.64 (10.26) 0.23 (1.55) <0.0001
Lifetime Heroin Exposure (g-years) 7.56 (11.40) 0.00 (0.00) -
Buprenorphine Use 95.89% 0.00% -
Buprenorphine Dose (mg) 4.64 (4.77) 0.00 (0.00) -
Medication Use 30.14% 26.72% 0.5643
* – Chi Squared test, df = 1.
a – Data listed as percent positive
b – Data listed as Mean (± S.D.).
"g-years" refers to gram-years as lifetime heroin exposure
Table 3: Trauma Related Conditions
Condition SUD N-SUD P*
Medical Conditions
Ever Fitted 17.35% 3.82% <0.0001
Epilepsy† 3.65% 0.00% 0.0044
Vision Impairment 25.11% 34.35% 0.0514
Spectacle Use 17.35% 53.44% <0.0001
Diabetes 1.37% 6.11% 0.0381
Insulin Use† 4.11% 4.58% 0.5161
Traumatic Conditions
Fracture 63.47% 51.91% 0.0359
No. Fractures 2.19 (4.08) 1.045 (2.18) 0.0006
Surgery No. 0.26 (0.50) 0.13 (0.34) 0.0050
No. Fracture Surgeries 0.49 (1.16) 0.16 (0.46) 0.0002
No. Operations 2.10 (3.30) 2.37 (4.90) 0.5855
Bashed 64.06% 17.56% <0.0001
Assaulted 69.41% 22.90% <0.0001
Tooth Knocked Out 29.95% 12.21% <0.0001
* – Chi Squared test, df = 1, unless otherwise noted.
† – Fisher Exact test used.Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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Driving experience is detailed in Tables 4 and 5 and Fig-
ures 2 and 3 for continuous and categorical variables
respectively. There were slight differences in the age of
driving commencement 16.52 ± 4.34 vs. 17.96 ± 6.33
years (Student's t = -2.13, df = 171.16, P = 0.0345). How-
ever there were marked and important differences in the
mean numbers of years of driving which were 15.96 ±
8.50 vs. 25.54 ± 15.03 respectively (Student's t = -4.48, df
= 183.64, P < 0.0001). The mean number of years of driv-
ing in the SUD group is therefore 62.4% of the N-SUD
group. The frequency distribution histogram between
these two groups is shown in Figure 1B. The total number
of years of driving experience in the two groups was 2920
and 2708 years respectively. As shown in Table 4 most
other measures of driving trauma were more common in
the SUD group with the exception of the time of the last
crash. There were 7 deaths in car wrecks in the SUD group
but none in the N-SUD group (Student's t = 2.24, df = 215,
P = 0.0262).
As shown in Table 5 the SUD group had been involved
with more driving related incidents of almost all kinds
than the N-SUD group, with the exception of having been
rear ended, or having their car hit. Patients were also asked
Table 4: Driving Career – Continuous Variables
Condition SUD N-SUD U Z P-level*
Age Commence't Driving 16.52 (4.34) 17.96 (6.33) 12336.50 -2.087 0.0369
No. Years Driving 15.96 (8.50) 25.54 (15.03) 10821.00 -3.643 0.0003
No. Years Lost Licence 1.71 (3.60) 0.11 (0.31) 7404.50 8.225 0.0000
No. MBA's 0.83 (2.96) 0.22 (0.91) 12125.00 3.423 0.0006
No. MVA's 2.00 (3.30) 1.10 (1.32) 11734.00 2.592 0.0096
Date of Last Crash† 18/10/95 (18) 4/4/1994 (95) 3193.000 4.984 0.0000
No. Cars Hit 1.22 (2.78) 0.53 (0.85) 11844.00 2.787 0.0053
No. Cars Repaired 1.73 (3.59) 1.08 (1.60) 12982.50 1.431 0.1525
No. Cars Written Off 0.99 (2.46) 0.24 (0.53) 10414.00 4.937 0.0000
No. Killed 0.08 (0.49) 0.00 (0.00) 13624.00 2.225 0.0261
Data listed as mean (± S.D.).
* – Mann-Whitney U-Test
† – The format of dates is dd/mm/yyyy. The number is brackets refers to days as the S.D.
Abbreviations: MBA – motor bike accident; MVA – motor vehicle accident.
Table 5: Lifetime Driving History – Categorical Variables
Parameter Chi Squ Df O.R. C.I. P*
Driving Problems
Drive 5.99 1 0.41 0.18–0.89 0.0144
Lost Licence 63.83 1 7.70 4.38–13.63 <0.0001
Disqualified 55.36 1 6.99 3.92–12.55 <0.0001
Motor Bike Accident 12.41 1 3.00 1.54–5.94 0.0004
Motor Vehicle Accident 4.47 1 1.66 1.01–2.74 0.0346
Your Car Hit 2.62 1 0.70 0.44–1.10 0.1053
Hit Other Cars 19.90 1 3.09 1.81–5.30 <0.0001
Drunk Driving 9.89 1 7.55 1.81–66.90 0.0016
Drugged Driving 26.42 1 31.70 5.22–1290.43 <0.0001
Benzo Affected Driving 12.41 1 6.76 2.03–35.18 0.0008
Remember Accident 2.50 1 1.44 0.89–2.32 0.1142
Struck from behind 2.80 1 1.49 0.91–2.44 0.9430
Been Rear ended 2.80 1 1.49 0.91–2.44 0.9430
Hit a car from behind 6.49 1 1.90 1.13–3.25 0.0108
Rear ended Anyone 6.49 1 1.90 1.13–3.25 0.0108
Taken to Hospital 5.06 1 1.95 1.05–3.66 0.0244
Others to Hospital 2.09 1 2.00 0.93–4.37 0.0368
Anybody Killed# 5.03 1 - - 0.0249
Run Away from Crash† 21.92 1 26.37 4.31–1077.48 <0.0001
* – Chi Squared test, df = 1.
# – Listed result is for Chi Squared. Fisher Exact Test (two tails) result, P = 0.0293.
† – Odds ratio adjusted by the insertion of unity into the numerator of the N-SUD group to allow calculation to be performed.
£ – P value from Fisher Exact test.Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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about recall of their accidents (see the "remember acci-
dent" variable in Table 5), because one possible explana-
tion for an altered driving history in the two groups was a
drug induced amnesia for the accident. However there was
no evidence that differential recall was a significant con-
founding factor in the two groups (68.35% vs. 60.00%,
Chi Squared = 2.50, df = 1, P = 0.114). 37 SUD patients
described fleeing from the scene of an accident, whereas
none of the N-SUD described this behaviour (Fisher Exact
test P < 0.0001). When unity is introduced into the N-
SUD group to allow the calculation of an odds ratio and
confidence intervals (see Methods) this difference
remains significant (O.R. = 26.37, C.I. 4.31–1,077.48, P <
0.0001).
9 SUD patients vs. 0 N-SUD patients described fatalities
occurring in car accidents in which they were involved
(Fisher Exact test P = 0.029). These crashes were report-
edly responsible for the deaths of 17 people (Fisher Exact
test P = 0.0005). When the correction unity is introduced
into this analysis, this latter statistic remains significant
(Exact Test O.R. = 9.59, 95%C.I. 1.46–403.99, Yates Cor-
rected Chi Squ. = 5.75, P = 0.0165).
When all 17 categorical driving variables are combined in
sequential Chi squared table analyses the SUD group,
despite their younger age and significantly lesser driving
experience, are involved in significant motor vehicle inci-
dents more frequently (Chi Squ. = 199.50, df = 17, O.R. =
2.73, C.I. 2.36–3.15, P < 0.0001).
Figure 4A and 4B plots the number of cars hit and the
number of cars which required to be repaired respectively
in the two groups as a function of the duration of driving
career. As both of these two datasets were not normally
distributed square root transforms were applied prior to
multiple regression. In each case addictive status was
shown to be a signficant determinant of vehicular trauma
(cars hit F = 10.01, df = 2,343, P < 0.0001; and cars
repaired F = 171.79, df = 2,342, P < 0.0001).
Odds ratios of various driving related events – categorical variables Figure 2
Odds ratios of various driving related events – categorical variables. Abbreviations: MBA – motor bike accident; MVA 
– motor vehicle accident; BZD – benzodiazepines; FX – effects. Note that the numerators for ran away from crash and any-
body killed have been adjusted as described to allow calculation of an odds ratio, as the numbers identified in the N-SUD group 
were zero. Note the scale break. * – P < 0.05. ** – P < 0.01. *** – P < 0.001. **** – P < 0.0001.
Odds Ratio N-SUD vs. SUD, Driving Related Events
- Categorical Variables
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Discussion
The main findings of this self-report cross-sectional survey
study are that, notwithstanding that the SUD group were
10.5 years younger and had a mean driving history which
is only 62.4% of the length of the comparator group, the
SUD group scored worse on many measures of trauma
including fracture, fracture surgeries, age adjusted num-
bers of surgical operations, experience of personal vio-
lence, assault on the person and traumatic dental
avulsion. They had significantly elevated driving related
event odds ratios for many non-drug related driving inci-
dents, significantly elevated odds ratios of benzodi-
azepine, alcohol and opiate affected driving, greatly
elevated rates of crude rates of years of licence lost, and
numbers of motor cycle and motor vehicle crashes,
including 17 fatalities compared to none, and many times
the rate of people who had left the scene of an accident.
These differences did not appear to be related to untoward
rates of medical conditions in SUD patients, and the rate
of visual impairment, wearing of spectacles, diabetes and
insulin use were found either not to be elevated in the
SUD group, or the differences suggested the SUD group
enjoyed better health. However for both a history of fits
and a diagnosis of epilepsy the SUD group was signifi-
cantly worse.
Summary odds ratios (and confidence intervals) were
derived of 10.07 (8.80–14.72) for drug use in 9 categories,
3.64 (2.98–4.80) for 5 kinds of trauma, and 2.73 (2.36–
3.15) for 17 kinds of driving related adverse events. This
analysis therefore describes an interesting parallel
between non-vehicular trauma on the one hand and
trauma and adverse events occurring on the road. This
association would be consistent with the view that high
levels of trauma and chaos inherent in the SUD lifestyle
are demonstrated in many ways both on and off the road.
Indeed since it is frequently the case in Australia that cars
are the locus for conducting drug deals and shooting up
drugs, and are used to travel both to and from drug deals,
it would appear that findings such as those reported in the
present study are an almost obligatory part of the sub-
stance dependent lifestyle. Some of these findings are con-
sistent with those reported elsewhere from this nation
[21].
Relative crude rates of various continuous variables Figure 3
Relative crude rates of various continuous variables. # = Number. * – P < 0.05. ** – P < 0.01. *** – P < 0.001. **** – P 
< 0.0001.
Relative Incidence of Selected Continuous Variables
- Crude Rates
Years Driving
Yrs Lost Licence
# MBA's
# MVA's
# Cars hit
# Cars repaired
Cars written off
# Killed
No. Driving Related Events
0
1
2
3
4
5
6
7
15
16
C
o
m
p
a
r
a
t
i
v
e
 
R
a
t
e
s
 N-SUD
 SUD
****
****
*
*
****
*
**
*Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
Page 9 of 12
(page number not for citation purposes)
Scatterplots of A.: Number of cars hit and B.: Number of cars repaired by length of driving experience Figure 4
Scatterplots of A.: Number of cars hit and B.: Number of cars repaired by length of driving experience.
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Indeed the overall picture which emerges from this statis-
tical pattern is that SUD patients are more likely to drive
drug affected and to be involved in car crashes often by
colliding with the rear end of another vehicle, in crashes
in which they and others are more likely to be seriously
injured, sustain a fracture, have surgery, have someone
else taken to hospital, kill someone and then abscond
from the scene of an accident. Having said that it is impor-
tant to emphasize that such events nevertheless appear to
be rare even in the driving careers of this group of sub-
stance dependent patients. Literature reports of less driver
impairment after buprenorphine than methadone [39-
41] suggest that the present profile of addiction in
buprenorphine treated patients likely represents a best
case scenario for opiate dependent patients in agonist
maintenance treatment.
Such a grossly adverse driving profile would appear to
lend ample evidentiary support to new measures such as
the random drug testing presently being implemented on
the roads of many Australian states including Queensland
and overseas. In this regard, and taking cognizance of
recent statements that the evidentiary basis for such meas-
ures has been relatively lean in the recent literature [1], the
present study would appear to make a useful and timely
contribution to the literature.
Furthermore, and in accordance with other recent com-
ments that the driving habits of substance dependent
patients pose a serious public health threat to themselves
other motorists and pedestrians [21,42], the present find-
ings emphasize that the routinely chaotic lifestyle of
addiction impacts the community more directly than with
relation to the spread of BBV's such as HIV and Hepatitis
B and C. The HIV/AIDS and Hepatitis B and C epidemics
of course are of global concern and will continue to fea-
ture large in the public health landscape for many decades
to come. Particularly because the drugs policy debate is so
often cast primarily in terms of control of BBV's, findings
such as those described in the present report re-focus
attention on the immediate and seriously impacting
implications of the dimensions of addictive behaviour
patterns occurring in the public space which tend usually
to be conceptualized as largely private and individual
behaviour choices.
Some of the medical findings of this study are intriguing.
The relatively high rate of epilepsy and fits in this popula-
tion is of note and has been found in other drug depend-
ent groups. There are several possible explanations for this
including hypoxic brain damage sustained during over-
doses and suicide attempts, nutritional deficiency, trau-
matic brain injury, antidepressant and phenothiazine
medication and stimulant use. It is worth noting that epi-
lepsy may frequently be triggered by medial temporal
lobe damage and that this is close to an active zone of neu-
rogenesis from within the sub-ventricular zone and hip-
pocampal formation, which latter has been noted to be
damaged in addiction [43]. Reduced neuronogenesis has
been previously associated with increased gliogenesis and
the migration of glial progenitors laterally [44,45] into the
medial temporal lobes and thalamus which have been
found to hypertrophy in patients particularly addicted to
stimulants [46-48]. Lifetime stimulant exposure was
noted to be common in the present SUD sample. Hence it
is conceivable that such epileptic phenomena, whilst hav-
ing several alternative explanations, may also be part of a
pattern of accelerated age related damage [49,50] such as
was recently described in several organ systems in a careful
autopsy study from Sydney [51].
The fact that rate of insulin use in this group was the same
as a comparator group more than a decade their senior is
also fascinating. Insulin dependent diabetes has been
ascribed to heightened immunological activity, and the
immunosuppressed – immunostimulated state of sub-
stance dependence has been well described and is increas-
ingly of research interest [52]. The fact that there was no
difference in the rate of insulin use between the two
groups is therefore presumptive evidence for potentiated
immune mediated ageing occurring in pancreatic islets.
The findings of significantly elevated rates of dental
trauma in this group are consistent with previous reports
from this clinic [6]. SUD patients have notoriously defi-
cient dental care which is exacerbated in our location as
our water supply is not fluoridated. Whilst many factors
contribute to this including osteoporosis [53], stem cell
depression [54,55], immunodeficiency [56,57], infection
[58], poor nutrition [6], the smoking of tobacco and can-
nabis [59] and the use of other drugs such as ampheta-
mines which dry up secretions, clearly trauma is not to be
overlooked as an important and potentiating cause of
dental disease and potentially compounds nutritional
compromise.
The limitations of this study are several and are related
mainly to features of its design. Biological samples such as
blood, urine and hair [60,61] were not collected for quan-
titation of recent drug exposure. Detailed questions were
not asked in relation to the drugs which were most com-
monly associated with driving. On the road, closed road,
and driving simulator studies were not performed. These
all represent further refinements which may be applied as
extensions and later developments of the present study.
This study was a based on a self report questionnaire.
Although this may be open to criticism, such methods
have been found to provide useful and reliable data where
strict confidentiality is assured [21]. Furthermore this
study was performed on two clinical samples of conven-Substance Abuse Treatment, Prevention, and Policy 2008, 3:10 http://www.substanceabusepolicy.com/content/3/1/10
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ience, and therefore does not have the generalizability of
population based studies. Nevertheless as such studies are
relatively common in the literature, the present work
makes a useful contribution to the published literature
particularly in the context of increased interest in the ran-
dom testing of motorists for drug driving in many nations
and states, and the on-going debate in relation to drug
policy and their associated legal status, by providing fur-
ther detail on a clinical in treatment sample of the target
group. The finding that this clinic is responsible for a sub-
stantial fraction of both the episodes of buprenorphine
withdrawal and of buprenorphine patients (63.5% and
73.2% respectively) in Queensland 2001–2006 suggests
that the findings from this survey are generalizable to sim-
ilar patients across this state, and likely this nation.
Conclusion
In summary this study found that a clinical sample of opi-
ate dependent patients had a particularly adverse driving
history related to virtually all surveyed aspects of their
driving history, and was consistent with the generally high
level of other kinds of non-vehicular trauma in their lives,
despite being much younger and having driven for much
less time than a medical comparator group. This was
largely not explained by concomitant levels of medical ill-
ness likely to interfere with driving in the substance
dependent group. These findings are important in that
they have implications which support drug driving screen-
ing programs [32] and tend to broaden the usually rela-
tively narrow debate surrounding the management of
drug dependence to include a significant contribution
from motor vehicle and other trauma.
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